DZ2938A1 - Composition contenant un sensibilisant à l'insuline et son utilisation dans le traitement du diabètesucré. - Google Patents

Composition contenant un sensibilisant à l'insuline et son utilisation dans le traitement du diabètesucré.

Info

Publication number
DZ2938A1
DZ2938A1 DZ990238A DZ990238A DZ2938A1 DZ 2938 A1 DZ2938 A1 DZ 2938A1 DZ 990238 A DZ990238 A DZ 990238A DZ 990238 A DZ990238 A DZ 990238A DZ 2938 A1 DZ2938 A1 DZ 2938A1
Authority
DZ
Algeria
Prior art keywords
treatment
composition containing
diabetes mellitus
insulin sensitizer
sensitizer
Prior art date
Application number
DZ990238A
Other languages
English (en)
French (fr)
Inventor
Lisa Dr Benincosa
William Jusko
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10842389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DZ2938(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of DZ2938A1 publication Critical patent/DZ2938A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
DZ990238A 1998-11-12 1999-11-10 Composition contenant un sensibilisant à l'insuline et son utilisation dans le traitement du diabètesucré. DZ2938A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9824893.3A GB9824893D0 (en) 1998-11-12 1998-11-12 Novel method of treatment

Publications (1)

Publication Number Publication Date
DZ2938A1 true DZ2938A1 (fr) 2004-03-15

Family

ID=10842389

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ990238A DZ2938A1 (fr) 1998-11-12 1999-11-10 Composition contenant un sensibilisant à l'insuline et son utilisation dans le traitement du diabètesucré.

Country Status (40)

Country Link
EP (2) EP1759698A1 (cs)
JP (1) JP2003521455A (cs)
KR (2) KR20070048279A (cs)
CN (3) CN1771943A (cs)
AP (2) AP1580A (cs)
AR (2) AR029149A1 (cs)
AT (1) ATE366573T1 (cs)
AU (1) AU768303B2 (cs)
BG (2) BG65577B1 (cs)
BR (1) BR9915284A (cs)
CA (1) CA2350425C (cs)
CO (1) CO5150158A1 (cs)
CY (1) CY1106892T1 (cs)
CZ (1) CZ299801B6 (cs)
DE (1) DE69936533T2 (cs)
DK (1) DK1135128T3 (cs)
DZ (1) DZ2938A1 (cs)
EA (2) EA009192B1 (cs)
ES (1) ES2289833T3 (cs)
GB (1) GB9824893D0 (cs)
HK (1) HK1041202B (cs)
HR (1) HRP20010344B1 (cs)
HU (1) HUP0104262A3 (cs)
IL (1) IL143088A0 (cs)
MA (1) MA26759A1 (cs)
MY (1) MY128347A (cs)
NO (1) NO328391B1 (cs)
NZ (1) NZ527132A (cs)
OA (1) OA12193A (cs)
PE (1) PE20001239A1 (cs)
PL (1) PL349421A1 (cs)
PT (1) PT1135128E (cs)
RS (1) RS50130B (cs)
SK (1) SK286357B6 (cs)
TR (1) TR200101348T2 (cs)
TW (1) TWI234456B (cs)
UA (1) UA79730C2 (cs)
UY (2) UY25797A1 (cs)
WO (1) WO2000027341A2 (cs)
ZA (1) ZA200103793B (cs)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
AU2002367154A1 (en) * 2001-12-21 2003-07-15 Smithkline Beecham Corporation Dosing regimen for ppar-gamma activators
WO2012074375A1 (en) * 2010-12-01 2012-06-07 N.V. Nutricia Prevention or treatment of overweight and obesity in type 2 diabetic patients

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
MX15171A (es) * 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
US5061717A (en) * 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH0469331A (ja) * 1990-07-10 1992-03-04 Asahi Chem Ind Co Ltd 徐放性エマルジョン製剤
JP2572673B2 (ja) * 1990-07-25 1997-01-16 エスエス製薬株式会社 徐放性錠剤
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) * 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE69219136T2 (de) * 1991-08-26 1997-08-28 Pharmacia & Upjohn Co., Kalamazoo, Mich. Flüssiges nahrungsmittel, das 3-guanidinopropionsäure enthält
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5478853A (en) * 1992-10-12 1995-12-26 Adir Et Compagnie Thazolidinedione compounds
US5506245A (en) * 1992-10-12 1996-04-09 Adir Et Compagnie Thiazolidinedione compounds
CA2115587A1 (en) * 1993-02-18 1994-08-19 Hayato Kihara Styrene copolymers, polystyrene compositions, processes for producing styrene copolymers, and injection-molded articles
DE4317320A1 (de) * 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
FI961213L (fi) * 1993-09-15 1996-05-14 Sankyo Co Tiatsolidinidionien käyttö insuliinista riippumattoman sokeritaudin syntymisen ehkäisemiseksi tai viivyttämiseksi
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
AR029149A1 (es) 2003-06-18
ZA200103793B (en) 2002-06-05
RS50130B (sr) 2009-03-25
EP1135128A4 (en) 2003-07-16
EA200100539A1 (ru) 2001-12-24
PL349421A1 (en) 2002-07-29
AP2005003432A0 (en) 2005-12-31
UY25801A1 (es) 2000-08-21
HRP20010344B1 (en) 2008-02-29
CY1106892T1 (el) 2012-01-25
EP1759698A1 (en) 2007-03-07
HK1041202B (en) 2007-10-05
CZ20011656A3 (cs) 2002-06-12
KR20010080440A (ko) 2001-08-22
AU1719600A (en) 2000-05-29
TWI234456B (en) 2005-06-21
BG110061A (bg) 2008-12-30
PT1135128E (pt) 2007-10-12
EA009192B1 (ru) 2007-12-28
NZ527132A (en) 2005-01-28
SK286357B6 (sk) 2008-08-05
CN1235586C (zh) 2006-01-11
BG65577B1 (bg) 2009-01-30
PE20001239A1 (es) 2000-12-24
CN1354661A (zh) 2002-06-19
CN101244062A (zh) 2008-08-20
ATE366573T1 (de) 2007-08-15
DE69936533D1 (de) 2007-08-23
HUP0104262A2 (en) 2002-08-28
DE69936533T2 (de) 2008-03-13
EA200700968A1 (ru) 2008-06-30
HUP0104262A3 (en) 2003-06-30
YU37401A (sh) 2005-07-19
TR200101348T2 (tr) 2002-02-21
SK6422001A3 (en) 2001-12-03
CZ299801B6 (cs) 2008-11-26
HK1041202A1 (en) 2002-07-05
BG105569A (en) 2002-01-31
UY25797A1 (es) 2000-12-29
HRP20010344A2 (en) 2002-06-30
JP2003521455A (ja) 2003-07-15
CA2350425C (en) 2009-06-02
AU768303B2 (en) 2003-12-04
EP1135128A2 (en) 2001-09-26
NO20012301D0 (no) 2001-05-10
CA2350425A1 (en) 2000-05-18
NO20012301L (no) 2001-07-09
CO5150158A1 (es) 2002-04-29
IL143088A0 (en) 2002-11-10
EP1135128B1 (en) 2007-07-11
NO328391B1 (no) 2010-02-08
DK1135128T3 (da) 2007-11-05
MY128347A (en) 2007-01-31
WO2000027341A2 (en) 2000-05-18
WO2000027341A3 (en) 2000-09-08
KR20070048279A (ko) 2007-05-08
BR9915284A (pt) 2002-02-13
CN1771943A (zh) 2006-05-17
ES2289833T3 (es) 2008-02-01
OA12193A (en) 2006-05-09
AP1580A (en) 2006-02-24
MA26759A1 (fr) 2004-12-20
UA79730C2 (en) 2007-07-25
AR029317A1 (es) 2003-06-25
GB9824893D0 (en) 1999-01-06

Similar Documents

Publication Publication Date Title
IT8223312A0 (it) Dispositivo per l'applicazione in vasi sanguini e altre posizioni difficilmente accessibili, e suo impiego.
DE3885613D1 (de) Schutzkleidung gegen chemische und biologische mittel.
EP0684044A3 (en) A composition containing dendrimer and active ingredient.
DE68912237D1 (de) Dampfsensitive Zusammensetzung sowie diese enthaltende sterilisierungsanzeigende Zusammensetzung.
DK1183020T3 (da) (3-trihalogenmethylphenoxy)(4-halogenphenyl) til behandling af insulinresistens og type 2-diabetes
IL133142A0 (en) Treatment of diabetes with thiazolidinedione and metformin
FR2712501B1 (fr) Appareil médical, notamment défibrillateur implantable, à fonctions d'enregistrement Holter intégrées .
DE69829763D1 (de) Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii
FR2774687B1 (fr) Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
KR950702308A (ko) 분만예정시기를 결정하는 진단방법과 이목적에 사용되는 키트(diagnostic method for determining the susceptibility to delivery and reagent kit for use therefor)
MX9100710A (es) Agentes fitoprotectores que contienen isoxazolinas o isotiazolinas asi como nuevas isoxazolinas e isotiazolinas
DE3780891D1 (de) Integrierter head-up-display und anzeige-einheit.
DE69516066D1 (de) Flüssigkristallzusammensetzung und Zellen, die diese enthalten
IT1134548B (it) Composizione termostabile formatrice di polimero e suo impiego negli esami diagnostici di sostanze biologiche
DZ2938A1 (fr) Composition contenant un sensibilisant à l'insuline et son utilisation dans le traitement du diabètesucré.
DE69432274D1 (de) Quinoxalineverbindungen, diese enthaltende Flüssigkristallzusammensetzung sowie diese enthaltende Anzeigevorrichtung
DZ2564A1 (fr) Compositions pharmaceutiques pour le traitement dudiabète sucre et d'états associés.
DE69837089D1 (de) Behandlung der diabetes mit thiazolidindione und sulphonylurea
DE69524918D1 (de) Flüssigkristall, Flüssigkristallmischung und Flüssigkristallvorrichtung, die diese enthält
FR2653059B1 (fr) Article pour traitement de surface contenant un materiau de traitement loge in situ et liberable au moment de l'utilisation.
HUP0103262A3 (en) Medicament containing platinum complex compounds and the use thereof
FR2656927B1 (fr) Dispositif d'immunotest du type plaquette a plonger, et trousse contenant ce dispositif.
DE69003853D1 (de) Ferroelektrische Flüssigkristallzusammensetzung und Vorrichtung die diese enthält.
FR2702149B1 (fr) Application de la lamotrigine dans le traitement du neuro-sida.
FR2720276B1 (fr) Nouvelle utilisation thérapeutique des agents bétamimétiques et médicament en contenant.